Results 31 to 40 of about 83,483 (295)

Drug Repurposing: Far Beyond New Targets for Old Drugs [PDF]

, 2012
Repurposing drugs requires finding novel therapeutic indications compared to the ones for which they were already approved. This is an increasingly utilized strategy for finding novel medicines, one that capitalizes on previous investments while ...
B Flachner, B Munos, BK Lin, CG Wermuth, CR Chong, D Curley, D Schuster, D Shigemizu, F Briansó, F Prinz, FS Collins, G Steinbach, GMS Silva Da, J Mestres, J Mestres, J Mestres, J. Mestres, JO Yang, K Sanderson, K Seibert, M Campillos, M Cases, MA Lindsay, MJ Keiser, P Cuatrecasas, RF Service, RG Kurumbail, RT Strachan, S Zhao, SH Sleigh, SL Kinnings, T Kawamori, T. I. Oprea, TD Warner, TI Oprea, TI Oprea, TI Oprea, TI Oprea, TT Ashburn, W Weber, WL Lipworth   +40 more
core   +1 more source

Klotho pathways, myelination disorders, neurodegenerative diseases, and epigenetic drugs [PDF]

, 2020
In this review we outline a rationale for identifying neuroprotectants aimed at inducing endogenous Klotho activity and expression, which is epigenetic action, by definition. Such an approach should promote remyelination and/or stimulate myelin repair by
Chen, Xiaohong, Faller, Douglas V., Glavas, Ioannis P., Harpp, David N., Kanara, Iphigenia, Kodukula, Krishna, Mavrakis, Anastasios N., Moos, Walter H., Pernokas, Julie, Pernokas, Mark, Pinkert, Carl A., Powers, Whitney R., Sampani, Konstantina, Steliou, Kosta, Vavvas, Demetrios G., Zamboni, Robert J.   +15 more
core   +1 more source

COVID infection in 4 steps: Thermodynamic considerations reveal how viral mucosal diffusion, target receptor affinity and furin cleavage act in concert to drive the nature and degree of infection in human COVID-19 disease

Heliyon, 2023
We have developed a mechanistic model of SARS-CoV-2 and SARS-CoV infection, exploring the relationship between the viral diffusion in the mucosa and viral affinity for the angiotensin converting enzyme 2 (ACE2) target. Utilising the structural similarity
Marko Popovic, Jennifer H. Martin, Richard J. Head   +2 more
doaj   +1 more source

Repurposing – second life for drugs [PDF]

Pharmacia, 2022
Drug repurposing refers to finding new indications for existing drugs. The paradigm shift from traditional drug discovery to drug repurposing is driven by the fact that new drug pipelines are getting dried up because of mounting Research &amp ...
Porkodi Ayyar, Umamaheswari Subramanian
doaj   +3 more sources

Understanding tissue morphology: model repurposing using the CoSMoS process [PDF]

, 2014
We present CoSMoS as a way of structuring thinking on how to reuse parts of an existing model and simulation in a new model and its implementation. CoSMoS provides a lens through which to consider, post-implementation, the assumptions made during the ...
Bown, James L., Deeni, Yusuf Y., Khalil, Hilal S., Li, Ye, Sampson, Adam T.   +4 more
core   +3 more sources

Drug reprofiling history and potential therapies against Parkinson’s disease

Frontiers in Pharmacology, 2022
Given the high whittling down rates, high costs, and moderate pace of new medication, revelation, and improvement, repurposing “old” drugs to treat typical and uncommon illnesses is progressively becoming an appealing proposition. Drug repurposing is the
Komal Latif, Aman Ullah, Anastasiia D. Shkodina, Anastasiia D. Shkodina, Dmytro I. Boiko, Zakia Rafique, Badrah S. Alghamdi, Badrah S. Alghamdi, Mohamed A. Alfaleh, Mohamed A. Alfaleh, Ghulam Md. Ashraf   +10 more
doaj   +1 more source

A target repurposing approach identifies N-myristoyltransferase as a new candidate drug target in filarial nematodes [PDF]

, 2014
Myristoylation is a lipid modification involving the addition of a 14-carbon unsaturated fatty acid, myristic acid, to the N-terminal glycine of a subset of proteins, a modification that promotes their binding to cell membranes for varied biological ...
Carlow, Clotilde K. S., Chapman, Melissa S., Galvin, Brendan D., Li, Zhiru, Pollastri, Michael P., Poole, Catherine B., Villemaine, Estelle, Wyatt, Paul G.   +7 more
core   +4 more sources

A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes [PDF]

, 2014
Novel drugs are required for the elimination of infections caused by filarial worms, as most commonly used drugs largely target the microfilariae or first stage larvae of these infections.
AL Petersen, B Dembele, BM Bronsvoort, C Bourguinat, C Bourguinat, Charles D. Mackenzie, D Shahinas, D Wenkert, E Devaney, E Devaney, E Devaney, EB Garon, Eileen Devaney, Francis M. Sverdrup, G Chiosis, HK Choi, JC Pizarro, JE Allen, K Jhaveri, Kerry O'Neill, Kirsty Maitland, L Neckers, L Neckers, LC Cerchietti, LH Pearl, MA Felix, MG Basanez, MJ Taylor, PA Brough, R Kumar, R Pallavi, RE Howells, RM Jecock, S Subramanian, SA Eccles, SA Robertson, T Kim, T Taldone, T Taldone, T Taldone, TG Geary, TY Lin, V Gillan, Victoria Gillan, WF Schafer, X Lu, Y Du   +46 more
core   +2 more sources

Steps towards collective sustainability in biomedical research [PDF]

, 2018
The optimism surrounding multistakeholder research initiatives does not match the clear view of policies that are needed to exploit the potential of these collaborations.
Abbracchio, Maria Pia, Andreaus, Michele, Battaglia, Mario A., Costa, Ericka, Kapoor, Raj, Lubetzki, Catherine, Matarese, Giuseppe, Ristori, Giovanni, Salvetti, Marco, Zaratin, Paola   +9 more
core   +1 more source

Drug Repurposing in Parkinson’s Disease [PDF]

CNS Drugs, 2018
The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug development, attention is being turned to
Athauda, D, Foltynie, T
openaire   +3 more sources